<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750473</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000675</org_study_id>
    <secondary_id>NCI-2020-00366</secondary_id>
    <secondary_id>WINSHIP4933-19</secondary_id>
    <secondary_id>P30CA138292</secondary_id>
    <nct_id>NCT04750473</nct_id>
  </id_info>
  <brief_title>Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer</brief_title>
  <official_title>Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies how well fluciclovine positron emission tomography (PET)/computed&#xD;
      tomography (CT) and PSMA PET/CT work in helping doctors understand and classify invasive&#xD;
      lobular breast cancer in patients with invasive lobular breast cancer that is suspicious for&#xD;
      or has spread to other places in the body (metastasized). Fluciclovine and PSMA are&#xD;
      radiotracers used in PET/CT imaging scans that emit radiation. The PET/CT scan than picks up&#xD;
      the radiation being released to create a picture from within the body. Information learned&#xD;
      from this study may help researchers learn how to better identify metastatic disease in&#xD;
      invasive lobular breast cancer patients which will impact appropriate staging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Improve detection of metastasis with fluciclovine F18 (fluciclovine) and gallium Ga&#xD;
      68-labeled PSMA-11 (PSMA) PET versus best standard of care conventional imaging, as confirmed&#xD;
      with histology.&#xD;
&#xD;
      II. Determine concordance and discordance of invasive lobular breast cancer (ILC) detection&#xD;
      with PSMA versus fluciclovine PET, as confirmed with histology.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. Establish the role of circulating tumor deoxyribonucleic acid (DNA) (ctDNA) directed to&#xD;
      ESR1 and PI3K DNA in characterizing the degree of tumor burden as identified by metabolic&#xD;
      amino acid transport and tumor neovasculature receptor imaging.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) and undergo a PET/computed&#xD;
      tomography (CT) scan over 30 minutes. On a separate day, patients receive fluciclovine F18 IV&#xD;
      and undergo a PET/CT scan over 30 minutes.&#xD;
&#xD;
      After completion of study, patients are followed up in 5-10 business days, and then up to 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verified detection rate for metastasis</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Detection rates are compared between fluciclovine positron emission tomography (PET) and conventional imaging. Paired detection rates will be assessed using McNemar's test. Detection rates will be reported for each method, and 95% confidence intervals will be estimated using the Clopper-Pearson approach. Rates of concordant/discordant observations will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verified detection rate for invasive lobular breast cancer</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Compared between gallium Ga 68-labeled PSMA-11 PET, fluciclovine PET, and conventional imaging. Paired detection rates will be assessed using McNemar's test. Detection rates will be reported for each method, and 95% confidence intervals will be estimated using the Clopper-Pearson approach. Rates of concordant/discordant observations will be reported.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Presence or absence of metastasis</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will correlate circulating tumor deoxyribonucleic acid (ctDNA) results with the presence or absence of metastasis. ctDNA parameters will be summarized descriptively using mean, median, minimum/maximum, interquartile range, and standard deviation. ctDNA will be correlated with positron emission tomography uptake parameters using Pearson's or Spearman's correlation coefficient (where appropriate), as well as chi-squared tests, Fisher's exact tests, or analysis of variance if any variables are further categorized</description>
  </other_outcome>
  <other_outcome>
    <measure>Imaging results</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will correlate ctDNA results with the results of imaging.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anatomic Stage IV Breast Cancer AJCC v8</condition>
  <condition>Invasive Breast Lobular Carcinoma</condition>
  <condition>Metastatic Breast Lobular Carcinoma</condition>
  <condition>Prognostic Stage IV Breast Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan over 30 minutes. On a separate day, patients receive fluciclovine F18 IV and undergo a PET/CT scan over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluciclovine F18</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)</arm_group_label>
    <other_name>(18F)Fluciclovine</other_name>
    <other_name>(18F)GE-148</other_name>
    <other_name>18F-Fluciclovine</other_name>
    <other_name>[18F]FACBC</other_name>
    <other_name>Anti-(18f)FABC</other_name>
    <other_name>Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid</other_name>
    <other_name>Anti-[18F] FACBC</other_name>
    <other_name>Axumin</other_name>
    <other_name>Fluciclovine (18F)</other_name>
    <other_name>FLUCICLOVINE F-18</other_name>
    <other_name>GE-148 (18F)</other_name>
    <other_name>GE-148 F-18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68 Gozetotide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>GA-68 PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium Ga 68-labeled PSMA-11</other_name>
    <other_name>GALLIUM GA-68 GOZETOTIDE</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment naive biopsy proven ILC patients with ILC&#xD;
&#xD;
          -  Either: a) clinical or imaging suspicion of metastatic disease; or b) proven&#xD;
             metastatic disease but in whom there is suspicion of an even greater tumor burden that&#xD;
             could change therapy approach&#xD;
&#xD;
          -  Ability and willingness to undergo biopsy if needed per standard of care for possible&#xD;
             metastasis which could change therapy approach&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy. Qualitative or quantitative serum or urine pregnancy test will be done in&#xD;
             women of childbearing potential within 24 hours before PET&#xD;
&#xD;
               -  A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has&#xD;
                  not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been&#xD;
                  naturally postmenopausal for at least 12 consecutive months (if age &gt; 55 years);&#xD;
                  if the female subject is &lt; 55 years and she has been naturally postmenopausal for&#xD;
                  &gt; 1 year her reproductive status has to be verified by additional lab tests (&lt; 20&#xD;
                  estradiol OR estradiol &lt; 40 with follicle-stimulating hormone [FSH] &gt; 40 in women&#xD;
                  not on estrogen replacement therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Schuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Hospital/Winship Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Schuster, MD</last_name>
    <phone>404-712-4859</phone>
    <email>dschust@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget M. Fielder</last_name>
      <phone>404-727-6648</phone>
      <email>bfielde@emory.edu</email>
    </contact>
    <investigator>
      <last_name>David M. Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>David M Schuster</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Lobular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

